US FDA Grants Orphan Drug Designation to Gracell’s FasTCAR-enabled BCMA/CD19 dual-targeting CAR-T cell therapy, GC012F to Treat Multiple Myeloma.

by admin
0 comment

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy
WP2Social Auto Publish Powered By :